Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 78   

Articles published

ARNA 4.28 -0.23 (-5.10%)
price chart
Arena Pharmaceuticals Q4 Loss Widens
Arena Pharmaceuticals, Inc. (ARNA: Quote) Monday reported fourth-quarter net loss of $32.1 million or $0.15 per share, wider than last year's loss of $23.5 million or $0.11 per share.
Arena Pharmaceuticals, Inc. Registers High Short Interest
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Each share of Arena Pharmaceuticals Inc is priced at $4.67, which is 36.5% below the 52-week high.
Arena Pharmaceuticals, Inc. Short Interest Climbs by 0.2%
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), In a major negative the short interest in Arena Pharmaceuticals, Inc. shot up by 0.2% or 68,778 shares. The final shorts are 15.6% of the total floated shares. The positions increased from 37,730,047 shares on ...
Healthcare Sector Movers: Arena Pharmaceuticals, Inc. (ARNA), Acorda ...  WallStreet Scope
Stocks to Track - Cypress Semiconductor (CY), ZIOPHARM Oncology (ZIOP ...  Techsonian (press release)
Arena's Belviq Scripts Spike - Maintaining This Trajectory Important
Arena (NASDAQ:ARNA) investors had something to celebrate this past week when script sales of the anti-obesity drug Belviq were released by IMS Health.
Arena Pharmaceuticals, Inc. Registers High Short Percent of Float
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) are trading at $4.33. The price is 41.2% off the 52-week high and 24.7% off the 52-week low.
Piper Jaffray Lowers Price Target On Arena Pharmaceuticals (ARNA) By 6.25%  Bidness ETC
Brokerage Firm Initiation and Price Target on Arena Pharmaceuticals, Inc.  Wall Street Pulse
Arena Pharmaceuticals to Present at the 2015 RBC Capital Markets Healthcare ...
SAN DIEGO, Feb. 18, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA, -5.05% announced today that the company is scheduled to present a corporate overview and update at the 2015 RBC Capital Markets Healthcare Conference on Tuesday, ...
Share Price of Arena Pharmaceuticals, Inc. Drops by -3.01%
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has dropped 3.01% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 4.64% in the last 4 weeks.
Target Price and Average Rating Consensus on Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has received a Neutral rating from research analysts at Zacks with a rating of 3. The company has been rated an average of 2.29 by 7 Wall Street Analysts.
Arena's Belviq Slows At A Bad Time
New prescription numbers have been released by IMS Health for Belviq (see Table 1), the anti-obesity agent from Arena Pharmaceuticals (NASDAQ:ARNA). The 2.5% week-to-week improvement is a slight improvement over the previous year's gain of 1.0%.
Arena Pharmaceuticals Inc. (ARNA) Jumps 6.08% on February 25
Arena Pharmaceuticals Inc. ($ARNA) was among the biggest gainers on the Russell 2000 for Wednesday February 25 as the stock popped 6.08% to $4.71, representing a gain of $0.27 per share.